On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > BUSINESS
BUSINESS
- As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market
August 9, 2018
- Otsuka’s Half-Year Pharma Sales Up 4.1% on Global Brands
August 9, 2018
- Teijin Making Inroads into Biosimilar Arena with Sales Tie-Up for Enbrel Follow-On
August 9, 2018
- Kyorin Holdings President Pledges to Hit Midterm Management Targets; Desalex Performs Better-Than-Expected
August 9, 2018
- Sumitomo Dainippon Chief Rules Out Divestment of Cash-Cow LLPs
August 8, 2018
- Maviret Remains Japan’s Best-Selling Drug in April-June: IQVIA
August 8, 2018
- Ethical Drug Sales Down 4.6% in June: Crecon
August 8, 2018
- Drug Wholesalers Log Sluggish Price Settlement Rates as They Run Careful Negotiations under New Guidelines
August 7, 2018
- Japan Lifestyle-Related Disease Treatment Market to Subside, after Peaking in 2018: Fuji Keizai
August 7, 2018
- AnGes’ HGF Therapy Could Debut Before Year-End to Become 1st Gene Therapy in Japan; 2 More Products Anticipated in 2019
August 7, 2018
- Takeda, Whiz Partners to Set Up Joint Investment Fund to Spur Drug Ecosystem
August 6, 2018
- Amgen Astellas Seeks OK for Repatha Monotherapy Use in Statin-Intolerant Patients
August 6, 2018
- Rituxan Filed for Add’l Indication of Chronic Lymphocytic Leukemia
August 6, 2018
- Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
- AstraZeneca’s Japan Crestor Sales Dive 71%
August 3, 2018
- Ninlaro Production Site Opens in Russia: Takeda
August 3, 2018
- Thrombocytopenia Drug Mulpleta Earns FDA Approval: Shionogi
August 3, 2018
- Recomodulin Fails to Hit Primary Goal in PIII for Severe Sepsis with Coagulopathy: Asahi Kasei
August 3, 2018
- Eisai Neurology Chief Shows Eagerness on Alzheimer’s Combination Trials
August 2, 2018
- AstraZeneca’s AI Translation System Could Bring Huge Impact If Materialized: Japan R&D Chief
August 2, 2018
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…